An effective CTL peptide vaccine for Ebola Zaire Based on Survivors’ CD8+ targeting of a particular nucleocapsid protein epitope with potential implications for COVID-19 vaccine design

The 2013–2016 West Africa EBOV epidemic was the biggest EBOV outbreak to date. An analysis of virus-specific CD8+ T-cell immunity in 30 survivors showed that 26 of those individuals had a CD8+ response to at least one EBOV protein. The dominant response (25/26 subjects) was specific to the EBOV nucl...

Descripción completa

Detalles Bibliográficos
Autores principales: Herst, C.V., Burkholz, S., Sidney, J., Sette, A., Harris, P.E., Massey, S., Brasel, T., Cunha-Neto, E., Rosa, D.S., Chao, W.C.H., Carback, R., Hodge, T., Wang, L., Ciotlos, S., Lloyd, P., Rubsamen, R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd. 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186210/
https://www.ncbi.nlm.nih.gov/pubmed/32418793
http://dx.doi.org/10.1016/j.vaccine.2020.04.034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186210/
https://www.ncbi.nlm.nih.gov/pubmed/32418793
http://dx.doi.org/10.1016/j.vaccine.2020.04.034

Ejemplares similares